公司概覽
業務類別 Diagnostics & Research
業務概覽 Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest countryconcentrations.
公司地址 5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
電話號碼 +1 800 227-9770
傳真號碼 --
公司網頁 https://www.agilent.com
員工數量 18100
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Padraig McDonnell President, Director and Chief Executive Officer 美元 1.14M 06/02/2026
Ms. Meghan Henson Senior Vice President, Agilent and Chief Human Resources Officer -- 22/12/2025
Mr. Simon May Senior Vice President, Agilent and President, Life Sciences and Diagnostics Markets Group 美元 635.39K 22/12/2025
Mr. Jonah Prevost Kirkwood Senior Vice President, Agilent and Chief Commercial Officer, Commercial Organization -- 22/12/2025
Ms. Angelica A. Reimann Senior Vice President, Agilent and President, Agilent CrossLab Group 美元 591.35K 22/12/2025
Mr. Mike Zhang Senior Vice President, Agilent and President, Applied Markets Group -- 22/12/2025
Mr. Adam S. Elinoff Senior Vice President and Chief Financial Officer -- 22/12/2025
Mr. Michael Buckner Chief Legal Officer -- 04/05/2026
Mr. Timothy Charles Downs Vice President and Chief Accounting Officer -- 03/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Dow R. Wilson Chairman of the Board 08/09/2026
Dr. George A. Scangos,PhD Independent Director 06/02/2026
Ms. Judy L Brown Independent Director 06/02/2026
Dr. Otis W. Brawley,M.D. Independent Director 06/02/2026
Dr. Daniel K. Podolsky, M.D. Independent Director 06/02/2026
Mr. Pascal Soriot Independent Director 06/02/2026
Dr. G. Mikael Dolsten, M.D.,PhD Independent Director 06/02/2026
Ms. Susan H. Rataj Independent Director 06/02/2026
Mr. Glenn S. Boehnlein Independent Director 08/09/2026
Ms. Mala Anand Independent Director 06/02/2026
Mr. Padraig McDonnell President, Director and Chief Executive Officer 06/02/2026
 
所屬ETF (更新日期: 26/09/2026 02:00)
代號 名稱 佔比% ▼ 持有日期
IUSInvesco RAFI™ Strategic US ETF0.002%31/08/2026
EVUSiShares ESG Aware MSCI USA Value ETF0.002%31/08/2026
GDOCGoldman Sachs Future Health Care Eq ETF0.002%31/08/2026
ISPYProShares S&P 500 High Income ETF0.002%31/08/2026
DTDWisdomTree US Total Dividend ETF0.001%31/08/2026
BAMVBrookstone Value Stock ETF0.001%31/08/2026
MMIDMFS Active Mid Cap ETF0.001%31/08/2026
VSLUApplied Finance Valuation LgCp ETF0.001%31/08/2026
EQLALPS Equal Sector Weight ETF0.001%31/08/2026
XVViShares ESG Select Screened S&P 500 ETF0.001%31/08/2026
OALCOneAscent Large Cap Core ETF0.001%31/08/2026
USNZXtrackers Net Zero Pwy Par Alg US Eq ETF0.001%31/08/2026
EPSWisdomTree U.S. LargeCap Fund0.001%31/08/2026
GVUSGoldman Sachs MktBt Russell LgCpValEqETF0.001%31/08/2026
AAEQAlpha Architect US Equity 2 ETF0.001%31/08/2026
NULCNuveen ESG Large-Cap ETF0.001%31/08/2026
RXLProShares Ultra Health Care0.001%31/08/2026
CRBNiShares Low Carbon Optd MSCI ACWI ETF0.001%31/08/2026
DEUSXtrackers Russell US Multifactor ETF0.001%31/08/2026
RSPEInvesco ESG S&P 500 Equal Weight ETF0.001%31/08/2026
  1    2    3    4    5    6    7    8   9    10    11    12    13    14    15    16    17  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.